Get notified when TEVA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Operating Loss Driven By One-time Acquisition Charge (worsened) — Teva swung from a $455M operating profit to a $231M loss, primarily due to a $724M non-deductible IPR&D charge from the Emalex acquisition.
- Short-term Debt Surge (worsened) — Short-term debt increased nearly tenfold to $4.5B, indicating significant near-term refinancing needs.
Teva swings to operating loss on $700M Emalex deal; revenue slips 0.8% to $4.14B
Filed July 29, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 30, 2025 · ~1 min read
Key Changes
-
high
Operating income swung from a profit to a loss, driven by a acquired IPR&D charge from the Emalex acquisition.
MD&A: Operating Results verify on EDGAR → -
high
Net loss was, or per diluted share, compared to a profit a year earlier.
Key Financials view on EDGAR → -
high
Teva acquired Emalex Biosciences, adding ecopipam (EBS-101), a Phase 3 Tourette syndrome asset; the IPR&D was expensed immediately.
Notes: Acquisitions verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.
Partner
Trade TEVA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 7, 2026 · How we verify